CKChrisoula Kartanou

Chrisoula Kartanou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chrisoula Kartanou has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Vivo Mapping of Catecholaminergic Loss and Iron Deposition in Huntington's Disease

    by Edoardo R. de Natale, Heather Wilson, Efstratios Karavasilis, Athanasia Liozidou, Chrisoula Kartanou, Georgios Velonakis, Jens Kuhle, Ioannis Zalonis, Georgia Karadima, Leonidas Stefanis, et al.

    Background: The pathophysiology of Huntington's disease (HD) remains obscure. Magnetic resonance imaging (MRI) can reveal in vivo molecular changes related to disease pathology. Objectives: To investigate catecholaminergic neuronal integrity and subcortical brain iron accumulation in HD employing neuromelanin‐sensitive MRI, and quantitative susceptibility mapping (QSM‐MRI). Methods: Twenty‐five HD gene expansion carriers (HDGECs; 11 premanifest, mean predicted phenoconversion time 21.25 ± 8.28 years) and 25 healthy controls (HC) underwent clinical investigation, measurement of plasma neurofilament light chain (NfL) levels, neuromelanin‐sensitive, and QSM‐MRI on a 3 T scanner. For neuromelanin analysis, the substantia nigra (SN) and locus coeruleus (LC) areas and contrast‐to‐noise ratio (CNR) were computed. Regions of interest from the MuSus100 atlas were segmented for QSM‐MRI analysis, and susceptibility values extracted using the whole brain mask as reference. Results: Manifest HDGECs showed, on neuromelanin‐sensitive MRI analysis, reduced LC and SN areas, and LC CNR compared with HC ( P < 0.001). QSM analysis demonstrated increased susceptibility values in caudate, putamen, external and internal pallidum, and the subthalamic nucleus of manifest HGDECs ( P < 0.001). Higher susceptibility values in these regions correlated with clinical markers of disease burden, higher plasma NfL, and poorer neuropsychological outcomes in multiple domains ( P < 0.05). Smaller LC area correlated with higher plasma NfL ( P = 0.029). Higher susceptibility values in the caudate and putamen correlated with lower SN CNR ( P < 0.05). Conclusions: Our findings confirm widespread iron subcortical accumulation in HD, reveal significant noradrenergic neuronal loss, and describe dopaminergic alteration which may reflect ongoing pathology along the nigrostriatal pathway. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Partial Loss of FITM2 Function Causes Hereditary Spastic Paraplegia

    by Ainara Salazar-Villacorta, Laura M. Bond, Leehyeon Kim, Katherine Anagnostopoulou, Annarita Scardamaglia, Eugenia Filippakopoulou, Athina Ververi, Stephanie Efthymiou, Argirios Dinopoulos, David Murphy, et al.

    FITM2 encodes fat storage‐inducing transmembrane protein 2 (FIT2), a lipid diphosphatase in the ER that cleaves acyl‐CoAs and is crucial for ER homeostasis. In humans, homozygous null mutations in FITM2 are associated with a syndrome characterized by deafness and dystonia. Here, we report two families presenting with late childhood‐onset, slowly progressive limb spasticity, cerebellar features, and relatively preserved cognition, consistent with a complex hereditary spastic paraplegia (HSP) phenotype in whom exome sequencing revealed compound heterozygosity for FITM2 mutations. In each family, the affected probands carry one putative null allele and one G100R missense allele. Functional analyses demonstrated that the G100R allele is hypomorphic, with FIT2 protein levels reduced to 20% of wild type, leading to proportionately decreased enzyme activity. The occurrence of similar HSP disease phenotypes and the same hypomorphic mutation in these families suggests that the G100R mutation and its associated reduced enzyme activity represent a newly recognized clinical manifestation of FITM2 mutations, expanding the spectrum of conditions associated with this gene.